Observational Study
Copyright ©The Author(s) 2020.
World J Psychiatr. Jan 19, 2020; 10(1): 1-11
Published online Jan 19, 2020. doi: 10.5498/wjp.v10.i1.1
Table 2 Summary of the purpose and analyses of the components of the Food and Drug Administration pivotal clinical trial of Cognivue®
Validation of classification scoresPurpose: Assess the validity of the previously defined Cognivue® cut-off scores in a larger sample of subjects
Methods: Scores on Cognivue® and SLUMS were compared using regression and classification analyses. PPA and NPA were calculated
Assessment of retest reliabilityPurpose: Compare scores from repeated administration of Cognivue® to assess retest reliability, compare findings to parallel results from SLUMS
Methods: Repeated Cognivue® and SLUMS testing was conducted in 2 sessions 1-2 wk apart with regression and rank linear regression analysis being performed
Assessment of score psychometrics vs other neuropsychological testsPurpose: Compare scores on Cognivue® and other neuropsychological tests to describe relationship and compare them to SLUMS
Methods: 401 participants completed 10 different tests [SLUMS, SLUMS-clock drawing1, SLUMS-animal naming1, RAVLT, TMT-A, TMT-B, Benton JOLO, figural memory, PPB, HVCS, GDS (15-item)]; rank linear regression analysis and factor analysis performed